CCM Biosciences
CCM Biosciences, a New Jersey-based biopharmaceutical company, innovates new drugs and diagnostic tests.
Founded
2010CCM Biosciences, a New Jersey-based biopharmaceutical company, innovates new drugs and diagnostic tests.
CCM Biosciences, founded in Mount Laurel, New Jersey, is a biopharmaceutical company dedicated to developing innovative drugs and companion diagnostic tests. The company's core mission is to advance healthcare through cutting-edge science and technology, focusing on various therapeutic areas. Their product pipeline includes novel treatments and diagnostic tools across multiple scientific disciplines such as RAS Sciences, PROTAC Sciences, Immune Sciences, Protein Upregulation, and Nanothera Sciences. CCM Biosciences aims to address unmet medical needs and improve patient outcomes globally.
Notable affiliated individuals include the management team, board of directors, and scientific advisors who bring extensive expertise in biotechnology and pharmaceuticals. The company is backed by Chakrabarti Capital Management (CCM), a seed-stage investor operating out of an Evergreen Fund. Key achievements of CCM Biosciences include the development of proprietary platforms for small molecule discovery, drug delivery, biologics discovery, and enzyme engineering. Their impact is marked by significant advancements in drug development and diagnostics, contributing to the broader healthcare landscape.
Companies similar to CCM Biosciences include CC Biotech, Bioscience Pharma Partners, Conjupro Biotherapeutics and CMD Bioscience.
CCM Biosciences was founded in 2010.
CCM Biosciences' headquarters is located in Mount Laurel, NJ, US.
CCM Biosciences' most recent funding round was for $25M (USD) in August 2023.
As of Aug 30, 2023, CCM Biosciences has disclosed funding of $25M (USD). Undisclosed round amounts are excluded.
CCM Biosciences has 50 employees as of Feb 4, 2024.
CMD Bioscience
